The Bio Report Levine Media Group

Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.

Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

Jeremiah Robison, CEO of Cionic, discusses the company’s Neural sleeve, how functional electronical stimulation helps people with movement disorders walk, and how the use of adaptive algorithms continuously optimizes the stimulation it delivers.

Pete Carlson, CEO of Spectral AI, discusses the company’s AI-driven DeepView System for assessing burns, how it provides clinicians an objective and immediate assessment of a wound’s healing potential, and how it changes outcomes for patients.

New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number of biopharmaceutical companies. One place that’s seeking to serve as both a home to innovative companies and facilitate collaborations is Cure, which describes itself as a healthcare innovation campus. We spoke to Seema Kumar, CEO of Cure, about how it operates, its various initiatives, and what can be done to accelerate the movement of innovative technologies from the lab to the marketplace.

Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 billion in 2022. M&A activity jumped to $140 billion from $78 billion during the same period. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about its Global Trends in R&D 2024 report, what he’s watching, and why the new patent cliff for the industry will be less threatening than the last one.